A Phase 1 interventional study of LY4167586 and Placebo in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Not yet recruiting at 12 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical Research Unit (CRU), each stay lasting between approximately 8 and 10 nights.
6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's planned enrollment of 617 is above the median of 77 across 5,084 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,095 studies on the registry; 142 are open to participants now.
Of its 535 completed or terminated interventional studies of FDA-regulated products, 356 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A, B, D, and E
Have a body mass index (BMI) of greater than or equal to 30 kilograms per square meter (kg/m²) or 27 to less than 30 kg/m² and previously diagnosed with at least one of the following weight-related comorbidities:
Part C
Part D
Part E
Exclusion Criteria:
LY4167586 administered subcutaneously (SC)
Drug: LY4167586
LY4167586 administered SC
Drug: LY4167586
LY4167586 administered SC
Drug: LY4167586
LY4167586 administered SC
Drug: LY4167586
LY4167586 administered SC
Drug: LY4167586
Placebo administered SC
Drug: Placebo
administered SC
administered SC
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through Study Completion (Estimated as Week 89)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4167586
Time frame: Baseline up to Week 89
PK: Area Under the Concentration Time Curve (AUC) of LY4167586
Time frame: Baseline up to Week 89
Body Weight Observed Value
Time frame: Baseline up to Week 89
Change from Baseline in Body Weight
Time frame: Baseline up to Week 89
Percent Change from Baseline in Body Weight
Time frame: Baseline up to Week 89
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.